Clinical Trial Update: Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating intravitreal rhuFab V2 in combination with Visudyne for age-related macular degeneration has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Visudyne (verteporfin)
• rhuFab V2 (rhuFab V2)

Snippet

Sponsor: Genentech, Inc. | Conditions: Age-Related Maculopathy | Phase 1, Phase 2 | Status: COMPLETED